Related Experiment Video
Updated: May 16, 2026
Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
Published on: August 2, 2018
Is phosphoproteomics ready for clinical research?
1Department of Biochemistry, Purdue University, West Lafayette, IN 47907, United States.
Background:
For many diseases such as cancer where phosphorylation-dependent signaling is the foundation of disease onset and progression, single-gene testing and genomic profiling alone are not sufficient in providing most critical information. The reason for this is that in these activated pathways the signaling changes and drug resistance are often not directly correlated with changes in protein expression levels. In order to obtain the essential information needed to evaluate pathway activation or the effects of certain drugs and therapies on the molecular level, the analysis of changes in protein phosphorylation is critical.
Methods:
Existing approaches do not differentiate clinical disease subtypes on the protein and signaling pathway level, and therefore hamper the predictive management of the disease and the selection of therapeutic targets.
Conclusions:
The mini-review examines the impact of emerging systems biology tools and the possibility of applying phosphoproteomics to clinical research.
Insights
Phosphorylation analysis, not just gene testing, is crucial for understanding complex diseases like cancer. This approach reveals molecular pathway changes and aids in selecting effective therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Systems Biology
Background:
- Phosphorylation-dependent signaling pathways are fundamental to diseases like cancer.
- Single-gene testing and genomic profiling are insufficient for understanding pathway activation and drug resistance.
- Protein phosphorylation analysis is critical for evaluating molecular-level pathway changes and therapeutic effects.
Purpose of the Study:
- To highlight the limitations of current diagnostic approaches in differentiating disease subtypes at the molecular level.
- To explore the potential of systems biology tools in clinical research.
- To examine the application of phosphoproteomics for improved disease management.
Main Methods:
- Review of emerging systems biology tools.
- Exploration of phosphoproteomics techniques.
- Analysis of their application in clinical research.
Main Results:
- Current methods fail to differentiate disease subtypes based on protein and signaling pathway alterations.
- This lack of molecular-level insight hinders predictive disease management and targeted therapy selection.
- Emerging systems biology tools, particularly phosphoproteomics, offer a more comprehensive approach.
Conclusions:
- Phosphoproteomics holds significant promise for advancing clinical research.
- Systems biology tools can provide critical molecular insights for personalized medicine.
- Applying phosphoproteomics can lead to better disease subtyping and more effective therapeutic strategies.
